{
    "clinical_study": {
        "@rank": "9814", 
        "acronym": "ESCC-307PLAH", 
        "arm_group": [
            {
                "arm_group_label": "Chemoradiotherapy", 
                "arm_group_type": "Active Comparator", 
                "description": "The patients will receive radiation therapy QD, 5 days a week and receive paclitaxel IV \uff0cdosing schedule: 45mg/m2/w."
            }, 
            {
                "arm_group_label": "Erlotinib and chemoradiotherapy", 
                "arm_group_type": "Experimental", 
                "description": "The patients will receive radiation therapy QD, 5 days a week and receive paclitaxel IV (45mg/m2/w) and erlotinib PO QD."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to test the safety and effectiveness of erlotinib and\n      chemoradiotherapy in patients with unresectable esophageal or gastro-esophageal squamous\n      cancer ."
        }, 
        "brief_title": "Paclitaxel Plus Radiation With Erlotinib to Treat Esophageal Squamous Carcinoma", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Esophageal Squamous Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Squamous Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histologically confirmed squamous cell carcinoma of esophagus or Esophagogastric\n             Junction\n\n          2. Age >= 18\n\n          3. ECOG PS 0-2\n\n          4. Ineligibility for surgery\n\n          5. No prior palliative therapy\n\n          6. At least one bidimensionally measurable disease as defined by RECIST ver 1.1\n\n          7. Adequate organ function for treatment\n\n               -  Absolute neutrophil count (ANC)>=1000cells/mm3\n\n               -  Platelets >=100000 cells/mm3\n\n               -  Estimated creatinine clearance>=50mL/min, or serum creatinine<1.5 x institution\n                  upper limit of normal\n\n               -  Bilirubin=<1.5 x upper limit of normal(ULN)\n\n               -  AST(SGOT)=<2.5 x ULN (5.0xULN if hepatic metastases)\n\n               -  ALT(SGPT)=<2.5 x ULN (5.0xULN if hepatic metastases)\n\n               -  12-Lead electrocardiogram(ECG) with normal tracing or non-clinically significant\n                  changes that do not require medical intervention\n\n               -  QTc interval =<470 msec and without history of Torsades de Points or other\n                  symptomatic QTc abnormality\n\n               -  LVEF (by MUGA or echocardiogram) of >=50%.\n\n          8. The patient has provided signed informed consent and is amenable to compliance with\n             protocol schedules and testing.\n\n        Exclusion Criteria:\n\n          1. Previous treatment with small molecule EGFR tyrosine kinase inhibitors\n\n          2. Any major operation within 4 weeks of baseline disease assessment\n\n          3. Any clinically significant gastrointestinal abnormalities which may impair intake or\n             absorption of the study drug\n\n          4. CNS metastasis with continuous corticosteroid use within 4 weeks of baseline disease\n             assessment\n\n          5. Patients with known interstitial lung disease\n\n          6. Patients with uncontrolled or significant cardiovascular disease (AMI within 12\n             months,Unstable angina within 6 months, NYHA Class III, IV Congestive heart failure\n             or left ventricular ejection fraction below local institutional lower limit of normal\n             or below 45%, Congenital long QT syndrome, Any significant ventricular arrhythmia,\n             Any uncontrolled second or third degree heart block, Uncontrolled hypertension)\n\n          7. Previous or concurrent malignancy except for basal or squamous cell skin cancer\n             and/or in situ carcinoma of the cervix, or other solid tumors treated curatively and\n             without evidence of recurrence for at least 5 years prior to study entry.\n\n          8. Pregnant or breast-feeding women\n\n          9. Other severe acute or chronic medical condition or laboratory abnormality that may\n             increase the risk associated with trial participation or investigational product\n             administration or may interfere with the interpretation of trial results and, in the\n             judgment of the investigator, would make the patient inappropriate for entry into\n             this trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01752205", 
            "org_study_id": "ESCC-307PLAH-XJM"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Chemoradiotherapy", 
                    "Erlotinib and chemoradiotherapy"
                ], 
                "description": "45mg/m2/w,total 6 weeks", 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Erlotinib and chemoradiotherapy", 
                "description": "150mg/d,days 1-42,total 6 weeks", 
                "intervention_name": "Erlotinib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Chemoradiotherapy", 
                    "Erlotinib and chemoradiotherapy"
                ], 
                "intervention_name": "Radiation therapy", 
                "intervention_type": "Radiation", 
                "other_name": "radiation therapy QD, 5 days a week,95%PTV 60Gy/2Gy/30f,total 6 weeks"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Paclitaxel", 
                "Erlotinib"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Esophageal Squamous Carcinoma", 
            "Erlotinib", 
            "Chemoradiotherapy"
        ], 
        "lastchanged_date": "December 16, 2012", 
        "location": {
            "contact": {
                "email": "jmxu2003@yahoo.com", 
                "last_name": "Xu jianming, M.D.", 
                "phone": "86-10-66947176"
            }, 
            "contact_backup": {
                "email": "chuanhuazhao@163.com", 
                "last_name": "Zhao chuanhua", 
                "phone": "86-10-66947179"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing"
                }, 
                "name": "307 Hospital of PLA"
            }, 
            "investigator": {
                "last_name": "Zhao chuanhua", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Phase III Study: Paclitaxel Plus Radiation Therapy With or Without Erlotinib in Treating Patients With Esophageal Squamous Carcinoma", 
        "overall_contact": {
            "email": "jmxu2003@yahoo.com", 
            "last_name": "Xu jianming, M.D.", 
            "phone": "861051128358"
        }, 
        "overall_official": {
            "affiliation": "The Affiliated Hospital of the Chinese Academy of Military Medical Science", 
            "last_name": "Xu jianming, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression free survival", 
            "safety_issue": "Yes", 
            "time_frame": "2 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01752205"
        }, 
        "responsible_party": {
            "investigator_affiliation": "The Affiliated Hospital of the Chinese Academy of Military Medical Sciences", 
            "investigator_full_name": "Xu jianming", 
            "investigator_title": "The Affiliated Hospital of the Chinese Academy of Military Medical Sciences", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Tumor response rate", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "disease control rate", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "overall survival", 
                "safety_issue": "Yes", 
                "time_frame": "5 year"
            }, 
            {
                "measure": "adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "5 year"
            }
        ], 
        "source": "The Affiliated Hospital of the Chinese Academy of Military Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "The Affiliated Hospital of the Chinese Academy of Military Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}